Dover Advisors LLC Boosts Position in CME Group Inc. $CME

Dover Advisors LLC raised its stake in CME Group Inc. (NASDAQ:CME) by 95.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,597 shares of the financial services provider’s stock after purchasing an additional 2,734 shares during the period. Dover Advisors LLC’s holdings in CME Group were worth $1,512,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Caldwell Trust Co boosted its holdings in shares of CME Group by 116.3% in the 3rd quarter. Caldwell Trust Co now owns 93 shares of the financial services provider’s stock valued at $25,000 after buying an additional 50 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in CME Group in the third quarter valued at $27,000. Financial Consulate Inc. purchased a new position in shares of CME Group during the third quarter worth about $28,000. Sagard Holdings Management Inc. purchased a new position in shares of CME Group during the second quarter worth about $30,000. Finally, Corundum Trust Company INC acquired a new stake in shares of CME Group during the third quarter worth about $30,000. Institutional investors and hedge funds own 87.75% of the company’s stock.

Key CME Group News

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: CME’s formal announcement to offer 24/7 trading for crypto futures and options — a move that addresses the timing gap with always‑on spot crypto markets and could lift ADV and fee revenue; the company cited record crypto notional volume in 2025. CME Group to Launch 24/7 Cryptocurrency Futures and Options Trading on May 29
• Positive Sentiment: Widespread coverage emphasizes the practical impacts — continuous trading can reduce “CME gaps,” boost institutional flow and expand crypto derivatives ADV, supporting the bullish thesis for trading‑fee growth. CME targets May launch for 24/7 crypto derivatives trading
• Positive Sentiment: Analyst/fin‑media bullishness — some outlets include CME among top picks, arguing the firm converts market volatility into trading revenue, which supports the stock’s rally. 2 Best Stocks to Buy Right Now for February
• Neutral Sentiment: Macro/market context — broader market moves (small‑cap rotation and sector flows) could be influencing intraday moves in financials/exchanges but are not specific to CME’s fundamentals. Small Caps Stage Quiet Comeback As AI Trade Shows Cracks
• Neutral Sentiment: Reported short‑interest data appears immaterial or inconsistent (no meaningful change reported); it isn’t currently signaling a large positioning risk.
• Negative Sentiment: Insider selling — director Martin J. Gepsman sold 300 shares; small in size but noteworthy as a disclosed insider sale. Insider Sale: Martin J. Gepsman
• Negative Sentiment: Critical takeaways — at least one outlet warns of risks to the CME thesis (valuation and competitive/operational risks), which could temper enthusiasm if amplified by further negative coverage. 2 Reasons CME is Risky and 1 Stock to Buy Instead

CME Group Price Performance

Shares of NASDAQ CME opened at $308.09 on Friday. The stock has a fifty day moving average price of $283.19 and a 200 day moving average price of $274.78. CME Group Inc. has a 1-year low of $246.91 and a 1-year high of $309.35. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.03 and a quick ratio of 1.02. The company has a market cap of $111.10 billion, a PE ratio of 27.61, a P/E/G ratio of 3.60 and a beta of 0.27.

CME Group (NASDAQ:CME) last announced its quarterly earnings data on Wednesday, February 4th. The financial services provider reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.75 by $0.02. CME Group had a net margin of 62.45% and a return on equity of 14.65%. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.64 billion. During the same period in the previous year, the company posted $2.52 EPS. CME Group’s revenue was up 8.1% compared to the same quarter last year. Sell-side analysts forecast that CME Group Inc. will post 10.49 EPS for the current year.

CME Group Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Tuesday, March 10th will be issued a dividend of $1.30 per share. This is an increase from CME Group’s previous quarterly dividend of $1.25. This represents a $5.20 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, March 10th. CME Group’s dividend payout ratio is currently 44.80%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CME. TD Cowen upped their target price on CME Group from $305.00 to $328.00 and gave the company a “buy” rating in a research report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on CME Group from $312.00 to $316.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. Raymond James Financial lowered their target price on shares of CME Group from $311.00 to $310.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Royal Bank Of Canada upped their price target on shares of CME Group from $295.00 to $302.00 and gave the company a “sector perform” rating in a research report on Thursday, February 5th. Finally, Morgan Stanley raised their price objective on shares of CME Group from $319.00 to $340.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $299.53.

Insider Activity

In other news, Director Martin J. Gepsman sold 300 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $305.90, for a total value of $91,770.00. Following the completion of the sale, the director directly owned 24,999 shares of the company’s stock, valued at $7,647,194.10. This trade represents a 1.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Dennis Suskind sold 748 shares of CME Group stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $300.00, for a total value of $224,400.00. Following the completion of the sale, the director owned 2,699 shares in the company, valued at approximately $809,700. This trade represents a 21.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 26,048 shares of company stock worth $7,054,920 in the last three months. 0.30% of the stock is currently owned by company insiders.

CME Group Profile

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.